Jessica Li

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

P. Ganly, S. O'brien, C. Tam, 2022, The New England journal of medicine.

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

P. Ganly, S. O'brien, C. Tam, 2022, Blood.

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

M. Waltham, S. Opat, V. Ramakrishnan, 2023, Blood advances.